Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
Enliven Therapeutics (Nasdaq: ELVN) has announced details for the presentation of updated ELVN-001 Phase 1a data at the ESH-iCMLf 26th Annual John Goldman Conference on CML. The event will take place from September 27-29 in Prague, Czech Republic. ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia (CML) patients.
The oral presentation, titled "Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1 in CML," will be delivered by Dr. Fabian Lang from Goethe University Hospital on September 28, 2024, at 3:35 p.m. CEST. The presentation will be part of Scientific Session 5: New drugs and combinations. Enliven will make the presentation available on their website after the conference.
Enliven Therapeutics (Nasdaq: ELVN) ha annunciato i dettagli per la presentazione dei dati aggiornati della fase 1a di ELVN-001 durante la 26a Conferenza Annuale John Goldman su CML dell'ESH-iCMLf. L'evento si terrà dal 27 al 29 settembre a Praga, Repubblica Ceca. ELVN-001 è un inibitore della chinasi a piccole molecole, potente e altamente selettivo, potenzialmente il migliore della categoria che mira alla fusione genica BCR-ABL nei pazienti affetti da leucemia mieloide cronica (CML).
La presentazione orale, intitolata "Sicurezza ed efficacia preliminari di ELVN-001, un inibitore selettivo del sito attivo di BCR::ABL1 nella CML," sarà effettuata dal Dr. Fabian Lang dell'ospedale universitario Goethe il 28 settembre 2024, alle 15:35 CEST. La presentazione farà parte della Sessione Scientifica 5: Nuovi farmaci e combinazioni. Enliven renderà la presentazione disponibile sul proprio sito web dopo la conferenza.
Enliven Therapeutics (Nasdaq: ELVN) ha anunciado detalles sobre la presentación de los datos actualizados de ELVN-001 en la fase 1a en la 26ª Conferencia Anual John Goldman sobre CML de ESH-iCMLf. El evento se llevará a cabo del 27 al 29 de septiembre en Praga, República Checa. ELVN-001 es un inhibidor de quinasa de molécula pequeña, potente y altamente selectivo, potencialmente el mejor de su clase que se dirige a la fusión génica BCR-ABL en pacientes con leucemia mieloide crónica (CML).
La presentación oral, titulada "Seguridad y eficacia preliminares de ELVN-001, un inhibidor selectivo del sitio activo de BCR::ABL1 en CML," será presentada por el Dr. Fabian Lang del Hospital Universitario Goethe el 28 de septiembre de 2024, a las 15:35 CEST. La presentación formará parte de la Sesión Científica 5: Nuevos medicamentos y combinaciones. Enliven pondrá la presentación a disposición en su sitio web después de la conferencia.
Enliven Therapeutics (Nasdaq: ELVN)는 ESH-iCMLf 제26회 John Goldman CML 회의에서 ELVN-001 1단계 데이터의 업데이트 발표 세부 사항을 발표했습니다. 이 행사가는 9월 27일부터 29일까지 체코 프라하에서 열립니다. ELVN-001은 만성 골수성 백혈병(CML) 환자의 BCR-ABL 유전자 융합을 목표로 하는 강력하고, 매우 선택적이며, 잠재적으로 최고의 소분자 키나제 억제제입니다.
“CML에서 BCR::ABL1의 선택적 활성 부위 억제제 ELVN-001의 초기 안전성 및 효능”이라는 제목의 구술 발표는 2024년 9월 28일 오후 3시 35분 CEST에 괴테대학교 병원의 Dr. Fabian Lang에 의해 진행될 예정입니다. 이 발표는 과학 세션 5: 신약 및 조합의 일환으로 이루어집니다. Enliven은 회의 후 자사 웹사이트에 발표 내용을 게재할 예정입니다.
Enliven Therapeutics (Nasdaq: ELVN) a annoncé les détails de la présentation des données mises à jour de ELVN-001 Phase 1a lors de la 26e Conférence Annuelle John Goldman sur la CML de l'ESH-iCMLf. L'événement se déroulera du 27 au 29 septembre à Prague, en République tchèque. ELVN-001 est un inhibiteur de kinases à petites molécules, puissant, hautement sélectif, potentiellement le meilleur de sa catégorie visant la fusion génique BCR-ABL chez les patients atteints de leucémie myéloïde chronique (CML).
La présentation orale, intitulée "Sécurité et efficacité préliminaires de l'ELVN-001, un inhibiteur sélectif du site actif de BCR::ABL1 dans la CML," sera présentée par le Dr. Fabian Lang de l'Hôpital Universitaire Goethe le 28 septembre 2024 à 15h35 CEST. La présentation fera partie de la Session Scientifique 5 : Nouveaux médicaments et combinaisons. Enliven mettra la présentation à disposition sur son site Web après la conférence.
Enliven Therapeutics (Nasdaq: ELVN) hat Details zur Präsentation aktualisierter ELVN-001 Phase 1a Daten auf der 26. Jahreskonferenz John Goldman zur CML des ESH-iCMLf bekannt gegeben. Die Veranstaltung findet vom 27. bis 29. September in Prag, Tschechische Republik, statt. ELVN-001 ist ein potenter, hochselektiver, potenziell erstklassiger kleiner Molekül-Kinase-Inhibitor, der die BCR-ABL-Genenfusion bei Patienten mit chronischer myeloischer Leukämie (CML) anvisiert.
Die mündliche Präsentation mit dem Titel „Vorläufige Sicherheit und Wirksamkeit von ELVN-001, einem selektiven aktiven Standortinhibitor von BCR::ABL1 bei CML“ wird am 28. September 2024 um 15:35 Uhr CEST von Dr. Fabian Lang vom Krankenhaus der Universität Frankfurt gehalten. Die Präsentation ist Teil der wissenschaftlichen Sitzung 5: Neue Medikamente und Kombinationen. Enliven wird die Präsentation nach der Konferenz auf ihrer Website zur Verfügung stellen.
- ELVN-001 Phase 1a data selected for oral presentation at a major CML conference
- ELVN-001 described as potentially best-in-class small molecule kinase inhibitor for CML treatment
- None.
BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced details for the updated ELVN-001 Phase 1a data, which was selected for an oral presentation at the upcoming European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference taking place September 27-29 in Prague, Czech Republic.
ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML).
Details of the oral presentation are as follows:
Title: Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1 in CML
Presenter: Fabian Lang, MD, Goethe University Hospital
Session: Scientific Session 5: New drugs and combinations
Session Date/Time: Saturday, September 28, 2024, 3:00 - 4:20 p.m. CEST
Presentation Time: 3:35 - 3:50 p.m. CEST / 9:35 - 9:50 a.m. ET
A copy of the presentation will be available by visiting the “Program Presentations & Publications” section of the Company’s website at www.enliventherapeutics.com.
About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help people with cancer not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven’s discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.
Contact
Investors
ir@enliventherapeutics.com
Media
media@enliventherapeutics.com
FAQ
What is ELVN-001 and what is it designed to treat?
When and where will the ELVN-001 Phase 1a data be presented?
Who will be presenting the ELVN-001 Phase 1a data at the CML conference?
What is the stock symbol for Enliven Therapeutics?
